About: Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases
Creator	Chan, Kuan, Rong Mok, Darren Ong, Eugenia Ooi, Eng
Source	Medline; PMC
abstract	The lack of vaccines against several important viral diseases necessitates the development of therapeutics to save lives and control epidemics. In recent years, therapeutic antibodies have received considerable attention due to their good safety profiles and clinical success when used against viruses such as respiratory syncytial virus, Ebola virus and Hendra virus. The binding affinity of these antibodies can directly impact their therapeutic efficacy. However, we and others have also demonstrated that the subtype of Fc-gamma receptors (FcγRs) engaged influences the stoichiometric requirement for virus neutralization. Hence, the development of therapeutic antibodies against infectious diseases should consider the FcγRs engaged and Fc-effector functions involved. This review highlights the current state of knowledge about FcγRs and FcγR effector functions involved in virus neutralization, with emphasis on factors that can affect FcγR engagement. A better understanding of Fc-FcγR interactions during virus neutralization will allow development of therapeutic antibodies that are efficacious and can be administered with minimal side effects.
has issue date	2015-11-02(xsd:dateTime)
bibo:doi	10.1586/14787210.2015.1079127
bibo:pmid	26466016
has license	cc-by-nc-nd
sha1sum (hex)	9b2f83db4c307ae17c146bb6625ddb01474bbd9a
schema:url	https://doi.org/10.1586/14787210.2015.1079127
resource representing a document's title	Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases
has PubMed Central identifier	PMC4673539
has PubMed identifier	26466016
schema:publication	Expert Rev Anti Infect Ther
resource representing a document's body	covid:9b2f83db4c307ae17c146bb6625ddb01474bbd9a#body_text
is schema:about of	named entity 'VIRAL DISEASES' named entity 'LIVES' named entity 'INVOLVED' named entity 'ALLOW' named entity 'AFFECT' named entity 'REQUIREMENT' named entity 'ANTIBODIES' named entity 'CONSIDERABLE' named entity 'VIRAL DISEASES' named entity 'RECEIVED' named entity 'VIRUS NEUTRALIZATION' named entity 'THERAPEUTICS' named entity 'SIDE EFFECTS' named entity 'ATTENTION' named entity 'RECEPTORS' named entity 'ENGAGEMENT' named entity 'therapeutics' named entity 'vaccines' named entity 'stoichiometric' named entity 'UNDERSTANDING' named entity 'EFFICACY' named entity 'HENDRA VIRUS' named entity 'MINIMAL' named entity 'THEIR' named entity 'RECENT' named entity 'EPIDEMICS' named entity 'EFFECTOR' named entity 'TREATMENT' named entity 'THERAPEUTIC ANTIBODIES' named entity 'THERAPEUTIC ANTIBODIES' named entity 'CURRENT STATE' named entity 'ADMINISTERED' named entity 'CONSIDER' named entity 'GOOD' named entity 'DIRECTLY' named entity 'IMPORTANT' named entity 'CLINICAL SUCCESS' named entity 'SUBTYPE' named entity 'VIRUSES' named entity 'FCGR' named entity 'THERAPEUTIC EFFICACY' named entity 'EBOLA VIRUS' named entity 'DEMONSTRATED' named entity 'HAVE' named entity 'KNOWLEDGE' named entity 'THEIR' named entity 'VACCINES' named entity 'BETTER' named entity 'SAFETY' named entity 'THESE' named entity 'DUE TO' named entity 'FUNCTIONS' named entity 'INFLUENCE' named entity 'FC RECEPTORS' named entity 'ENGAGED' named entity 'SAVE' named entity 'YEARS' named entity 'INFECTIOUS DISEASES' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'ABOUT' named entity 'DEVELOPMENT' named entity 'GAMMA' named entity 'BINDING AFFINITY' named entity 'REVIEW' named entity 'USED' named entity 'LACK' named entity 'IMPACT' named entity 'INTERACTIONS' named entity 'CONTROL' named entity 'However' named entity 'development' named entity 'receptors' named entity 'epidemics' named entity 'virus' named entity 'Hendra virus' named entity 'therapeutic antibodies' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software